- Home
- FGEN vs KALA Comparison
FGEN vs KALA Comparison
Compare FGEN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- KALA
- Stock Information
- Founded
- FGEN 1993
- KALA 2009
- Country
- FGEN United States
- KALA United States
- Employees
- FGEN N/A
- KALA N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- KALA Health Care
- Exchange
- FGEN Nasdaq
- KALA Nasdaq
- Market Cap
- FGEN 33.5M
- KALA 26.2M
- IPO Year
- FGEN 2014
- KALA 2017
- Fundamental
- Price
- FGEN $5.85
- KALA $5.82
- Analyst Decision
- FGEN Strong Buy
- KALA Strong Buy
- Analyst Count
- FGEN 1
- KALA 3
- Target Price
- FGEN $250.00
- KALA $14.00
- AVG Volume (30 Days)
- FGEN 61.5K
- KALA 77.6K
- Earning Date
- FGEN 08-05-2025
- KALA 08-05-2025
- Dividend Yield
- FGEN N/A
- KALA N/A
- EPS Growth
- FGEN N/A
- KALA N/A
- EPS
- FGEN N/A
- KALA N/A
- Revenue
- FGEN $6,996,000.00
- KALA N/A
- Revenue This Year
- FGEN N/A
- KALA N/A
- Revenue Next Year
- FGEN N/A
- KALA N/A
- P/E Ratio
- FGEN N/A
- KALA N/A
- Revenue Growth
- FGEN N/A
- KALA N/A
- 52 Week Low
- FGEN $4.50
- KALA $2.92
- 52 Week High
- FGEN $38.25
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- FGEN 43.29
- KALA 66.64
- Support Level
- FGEN $5.37
- KALA $4.36
- Resistance Level
- FGEN $5.73
- KALA $5.75
- Average True Range (ATR)
- FGEN 0.41
- KALA 0.54
- MACD
- FGEN 0.07
- KALA 0.08
- Stochastic Oscillator
- FGEN 77.78
- KALA 82.44
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.